News | December 27, 2010

Coronary Imaging System Detects Acute Stent Thrombosis With Lipid Core Plaque


December 27, 2010 – A case report in Circulation describes the association of stent thrombosis with lipid core plaque as detected by the LipiScan Coronary Imaging System. The LipiScan is the first and only FDA-approved system to provide a chemogram (map of lipid core plaque) within the imaged vessel via near-infrared (NIR) spectroscopy. The authors note that the case represents the first demonstration of acute stent thrombosis associated with disrupted lipid core plaque (LCP) as detected by NIR imaging with the LipiScan system.

The paper titled “Residual Thrombogenic Substrate After Rupture of a Lipid Rich Plaque – Possible Mechanism of Acute Stent Thrombosis? A Near-Infrared Spectroscopy Study” was published in Circulation (2010;122:2349-2350) under authors Sakhuja R., Suh W., Jaffer F. and Jang I.

"While stenting is an excellent means to treat flow restrictions caused by coronary plaques, it is in some cases complicated by thrombosis which may cause serious consequences,” said James E. Muller, M.D., founder and chief executive officer of InfraReDx. “This report by Sakhuja et al. describes the occurrence of thrombosis in a stent that ends in a lipid core plaque, a structure that contains substances known to be thrombogenic. This adds to the accumulating evidence that many complications of stenting – peristenting infarction, stent thrombosis and restenosis – are due not to features of the stent or stenting technique, but to the presence of a lipid core plaque at the stented site. We are pleased to make available the LipiScan IVUS Coronary Imaging System, which provides an easy and accurate method to detect lipid core plaque and thereby adds important information to the decision-making process."

The LipiScan IVUS Coronary Imaging System now combines both NIR (LipiScan) and intravascular ultrasound (IVUS) technologies. The IVUS feature provides an image of the plaque and coronary artery lumen, while the NIR feature provides rapid and accurate assessment of LCPs. Upon completion of a single catheter pullback, the LipiScan IVUS system is able to immediately generate and display a grayscale IVUS image of the coronary artery, along with a complete and co-registered chemogram within the imaged vessel.

For more information: www.infraredx.com


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now